Cargando…
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer. NEPC is characterized by the loss of androgen receptor (AR) signaling and transdifferentiation toward small-cell neuroendocrine (SCN) phenotypes, which results in resistance to AR-targeted therapy. NEPC resemble...
Autores principales: | Bae, Song Yi, Bergom, Hannah E., Day, Abderrahman, Greene, Joseph T., Sychev, Zoi E., Larson, Gabrianne, Corey, Eva, Plymate, Stephen R., Freedman, Tanya S., Hwang, Justin H., Drake, Justin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090553/ https://www.ncbi.nlm.nih.gov/pubmed/37065756 http://dx.doi.org/10.3389/fendo.2023.1093332 |
Ejemplares similares
-
Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts
por: Sychev, Zoi E., et al.
Publicado: (2023) -
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer
por: Shi, Xiaolei, et al.
Publicado: (2022) -
Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023) -
Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance
por: Krupková, Michaela, et al.
Publicado: (2018) -
Neuroendocrine Role for VGF
por: Lewis, Jo E., et al.
Publicado: (2015)